



FOR IMMEDIATE RELEASE: 2024/4/26

Listed Name: M3, Inc.
(TSE Prime Market, Ticker Code: 2413)
(<https://corporate.m3.com/en>)
Headquarters: 1-11-44 Akasaka, Minato-ku, Tokyo
Representative: Itaru Tanimura, Representative Director
Contact: Hirofumi Oba, Corporate Officer

**Notice Concerning Differences between Actual Non-Consolidated Results
for the Fiscal Year Ended March 31, 2024 and the Previous Fiscal Year Ended March 31, 2023**

This notice serves to provide information regarding the difference between actual non-consolidated results for the fiscal year ended March 31, 2024 and the results for the previous fiscal year ended March 31, 2023.

1. Differences between actual non-consolidated results for the fiscal year ended March 31, 2024 and the fiscal year ended March 31, 2023 (J-GAAP)

	Net sales	Operating profit	Ordinary profit	Profit
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen
Actual results for the fiscal year ended March 31, 2023 (A)	54,530	26,503	27,992	19,783
Actual results for the fiscal year ended March 31, 2024 (B)	51,520	23,596	84,032	75,943
Difference (B – A)	-3,010	-2,907	+56,039	+56,160
Difference (%)	-5.5	-11.0	+200.2	+283.9

2. Reason of differences

Net sales and operating profit for non-consolidated results for the fiscal year ended March 31, 2024 were lower than the previous fiscal year, mainly due to a year-on-year decline in sales of pharmaceutical marketing support business, affected by marketing budget constraints by pharmaceutical companies.

On the other hand, ordinary profit and profit were significantly higher than the previous fiscal year, due to the receipt of dividends from consolidated subsidiaries, as disclosed in the "Announcement of Receipt of Dividends from Consolidated Subsidiaries" released on March 22, 2024. As stated in the above announcement, there is no impact on the Company's consolidated financial results for the fiscal year ended March 31, 2024, since these are dividends from consolidated subsidiaries.